Contraindicated / Never Combine • CYP450 / P-gp Hepatic Clearance Inhibition • PMID: 15606436

Quercetin Senolytics + Tacrolimus/Cyclosporine: Acute Nephrotoxicity Risk

Quercetin and Fisetin are potent bioflavonoid inhibitors of P-glycoprotein efflux and enterocyte CYP3A4. Combining them with narrow-therapeutic-index immunosuppressants causes toxic blood level spikes, risking irreversible calcineurin-induced renal damage.

Pharmacokinetic Pathway, AUC Shift & Clinical Management Protocol

  • Primary Enzyme / Transporter Pathway: P-Glycoprotein (ABCB1) & Intestinal CYP3A4 Allosteric Inhibition
  • Predicted Exposure Shift (AUC / Cmax): +100% to +250% Immunosuppressant Trough Blood Levels (Nephrotoxic Spike)
  • Circadian Dosing Separation Rule: Systemic pharmacodynamic/irreversible pathway (7-day clinical washout required before switching)
  • Mechanism Deep-Dive: Cyclosporine and tacrolimus depend heavily on intestinal P-gp to restrict systemic absorption and hepatic CYP3A4 for systemic clearance. High-dose quercetin blocks both barriers simultaneously, doubling or tripling drug trough concentrations (Cmin) into toxic ranges.
  • Clinical Management Protocol: Strictly contraindicated. Patients on organ transplant immunosuppression, digoxin, or narrow-therapeutic-index oncology regimens must completely avoid high-dose quercetin and senolytic bioflavonoid stacks. Observe a 7-day washout before starting such therapies.
  • Recommended Lab Monitoring Test: Whole Blood Tacrolimus/Cyclosporine Trough Levels, Serum Creatinine & Potassium
  • Primary Reference: Hsiu SL, et al. Quercetin significantly increased the bioavailability of cyclosporine in healthy rats and human clinical cohorts. Life Sci. 2005;76(17):1917-1925. (PMID: 15606436) — Audited by Dr. Marcus Vance, Ph.D. (Clinical Pharmacology)
Plot 5-Half-Life Systemic Washout Curve → Decode Monitoring Lab Biomarker (CYSTATIN-C) → View Full Quercetin / Fisetin Senolytics Monograph →

Related Drug-Supplement Interaction Audits